Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S374000, C514S364000, C548S214000, C548S235000, C548S131000, C549S491000
Reexamination Certificate
active
07119112
ABSTRACT:
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfonamides, and compositions and methods utilizing sulfonamides that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.
REFERENCES:
patent: 5652236 (1997-07-01), Krauss
patent: 5925342 (1999-07-01), Adorante et al.
patent: 6172054 (2001-01-01), Clark
patent: 6172109 (2001-01-01), Zinke et al.
patent: 2004/0029771 (2004-02-01), Rigdon et al.
patent: WO 99/32101 (1999-07-01), None
Supuran et al., 1998, CAS:129:132963.
Do et al., “Chloride Secretion by Bovine Ciliary Epithelium: a Model of Aquenos Humor Formation”,Investigative Ophthalmology&Visual Science41:7: 1853-1860 (2000).
Ishii et al., “A human intermediate conductance calcium-activated potassium channel”,Proc. Natl. Acad. Sci. USA94: 11651-11656 (1997).
Jensen et al., “Characterization of the cloned human intermediate-conductance Ca2+-activated K+channel”,The American Physiological SocietyC848-C856 (1998).
Joiner et al., “hSK4, a member of a novel subfamily of calcium-activated potassium channels”,Proc. Natl. Acad. Sci. USA94: 11013-11018 (1997).
Logsdon et al., “A Novel Gene, hKCa4, Encodes the Calcium-activated Potassium Channel in Human T Lymphocytes”,The Journal of Biological Chemistry272:52: 32723-32726 (1997).
Neylon et al., “Molecular Cloning and Characterization of the Intermediate-Conductance Ca2+-Activated K+Channel in Vascular Smooth Muscle: Relationship Between KcaChannel Diversity and Smooth Muscle Cell Function”,Department of Neurobiology, Duke University Medical Center UltraRapid Communication, 1-11 (1999).
Serke et al., “Effect of Pilocarpine 4% in Combination with Latanoprost 0.005% or 8-iso Prostaglandin E20.1% on Intraocular Pressure in Laser-induced Glaucomatous Monkey Eyes”,Journal of Glaucoma10: 215-219 (2001).
Stumpff et al., “Regulation of Trabecular Meshwork Contractility”,Ophthalmologica214: 33-53 (2000).
Stumpff et al., “Stimulation of Maxi-K Channels in Trabecular Meshwork by Tyrosine Kinase Inhibitors”,Inv. Ophth.&Vis. Sci.40:7: 1404-1417 (1999).
Vandorpe et al., “cDNA Cloning and Functional Characterization of the Mouse Ca2+-gated K+Channel, mlK1”,The Journal of Biochemistry273:34: 21542-21553 (1998).
Vogalis et al., “An intermediate conductance K+channel in the cell membrane of mouse intestinal smooth muscle”,Biochimica et Biophysica Acta1371: 309-316 (1998).
Wang et al., “Effect of Latanoprost or 8-iso Prostaglandin E2Alone and in Combination on Intraocular Pressure in Glaucomatous Monkey Eyes”,Arch Ophthalmol118: 74-77 (2000).
Warth et al., “Molecular and functional characterization of the small Ca2+-regulated K+ channel (rSK4) of colonic cryps”,Eur. J. Physiol.438: 437-444 (1999).
Weiderholt et al., “The Regulation of Trabecular Meshwork and Ciliary Muscle Contractility”,Progress in Retinal and Eye Research19:3: 271-295 (2000).
Wiederholt et al., “Effect of Diuretics, Channel Modulators and Signal Interceptors on Contractility of the Trabecular Meshwork”,Ophthalmologica211: 153-160 (1997).
Zhang et al., “Three different Cl−channels in the bovine ciliary epithelium activated by hypotonic stress”,Journal of Physiology499:2: 379-389 (1997).
Atkinson Robert N.
McNaughton-Smith Grant A.
Reed Aimee D.
ICAgen Inc.
Saeed Kamal A.
Shiao Robert
Townsend and Townsend / and Crew LLP
LandOfFree
Sulfonamides as potassium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonamides as potassium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonamides as potassium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3687664